An FDA advisory committee recommended easing access to several popular wellness peptides, including BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, despite staff concerns about scant human data and safety risks.
The Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 in favor of including BPC-157 and later recommended KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A bulk drug substances list, which would allow compounding pharmacies to produce them under prescription.
FDA staff reviewers have recommended against adding these peptides, citing a near-total absence of human clinical trial data, weak preclinical evidence, and significant safety and labeling concerns.
The panel’s votes are nonbinding; the final decision rests with the FDA, but the direction signals a potential shift toward broader, regulated access through compounding rather than FDA approval.
Sources:
FDA advisory committee votes to add popular peptide BPC ...
FDA Committee Votes Favorably on BPC-157 and KPV ...
FDA considers widening access to peptides promoted by ...
FDA revamps peptide panel with industry advocates
US panel endorses more unproven if buzzy peptides
FDA panel supports broadening access to peptides ...
FDA panel recommends easing some peptide restrictions ...
RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access
Peptide Regulatory Tracker | FDA 503A & GLP-1 (2026)
Wellness peptides edge toward mainstream
FDA Appoints Longevity and Wellness Doctors with Peptide Industry ...
The future of peptides in the US is about to become clearer. Here's what you should know
WATCH LIVE: Day 2 of FDA advisory panel meeting to consider use of peptides